Advancing Precision Medicine in Mental Health Research: NetraMark Holdings Inc. and CAMH Collaboration
NetraMark Holdings Inc., a leading artificial intelligence company specializing in AI-powered precision analytics for clinical trials in the pharmaceutical industry, has partnered with the Centre for Addiction and Mental Health (CAMH) in Toronto to receive the prestigious Ontario Research Fund – Research Excellence (ORF-RE) Award. This collaboration will utilize NetraMark's NetraAI platform to analyze genetic and epigenetic data from studies on schizophrenia and major depressive disorder at CAMH, aiming to identify patient subpopulations and enhance precision treatment strategies.
The initiative seeks to uncover biological subtypes in psychiatric disorders through the analysis of genetic and epigenetic patterns, ultimately improving clinical trial outcomes for pharmaceutical sponsors in the psychiatric space. The deployment of NetraAI software on CAMH's research cluster is being facilitated by CAMH's Research IT team with support from NetraMark, ensuring the use of de-identified patient data to maintain data privacy and network security standards.
Dr. James Kennedy, Head of the Tanenbaum Centre for Pharmacogenetics at CAMH, highlighted the significance of the collaboration in exploring how genetic and epigenetic factors influence treatment response in psychiatric disorders. The partnership aims to personalize treatment for individuals with complex mental health conditions like schizophrenia and depression, leveraging the unique AI framework of NetraAI to uncover biologically grounded subpopulations for precision medicine approaches.
Dr. Joseph Geraci, Founder and Chief Scientific & Technology Officer of NetraMark, expressed pride in the collaboration with CAMH and the potential to advance psychiatric research through the integration of genomic and clinical datasets with NetraAI's explainable AI framework. The collaboration also includes the evaluation of an additional dataset to analyze cost effectiveness and broader health-system impacts of personalized patient care.
NetraAI stands out for its focus mechanisms that separate datasets into explainable and unexplainable subsets, enabling the derivation of insights and hypotheses to enhance clinical trial success rates. By utilizing explainable subsets, NetraAI can provide accurate insights into treatment responses and adverse events, contributing to improved patient care and trial outcomes in the pharmaceutical industry.
In conclusion, the partnership between NetraMark and CAMH represents a significant step towards advancing precision medicine in mental health research and improving clinical trial outcomes through innovative AI-powered analytics. The collaboration underscores the importance of leveraging AI technologies to drive research excellence and technological advancement in healthcare.